Month: September 2021
Excerpt from the Press Release: SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today completed its business combination with Locust Walk Acquisition Corp. (NASDAQ: LWAC). The resulting combined company (the Company) has been renamed “eFFECTOR Therapeutics, Inc.” and…
Read More
Excerpt from the Press Release: PLYMOUTH MEETING, Pa., Aug. 26, 2021 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it has received regulatory authorization from Brazil’s ANVISA (Agência Nacional de Vigilância Sanitária), the national health regulatory agency of Brazil,…
Read More
Excerpt from the Press Release: SAN FRANCISCO and LOS ANGELES, Aug. 26, 2021 /PRNewswire/ — Curebase, a company committed to democratizing access to clinical studies, and AppliedVR, a pioneer advancing the next generation of digital medicine, today announced a one-year partnership where AppliedVR will deploy the Curebase platform to run five clinical trials assessing the effectiveness of virtual reality-based (VR)…
Read More
Excerpt from the Press Release: SAN DIEGO, Aug. 26, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19, today announced promising preclinical results for its mRNA vaccine against SARS-CoV-2. STI-mRNA is comprised of proprietary designer Spike-encoding mRNAs to…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. today announced a partnership to integrate its comprehensive genomic profiling (CGP) and other testing services with Epic’s electronic medical record (EMR) system. Once completed, all providers who use Foundation Medicine’s instance of Epic will be able to electronically order Foundation Medicine tests within the Epic network.…
Read More
Excerpt from the Press Release: PALO ALTO, Calif. & SHANGHAI & PRINCETON, N.J.–(BUSINESS WIRE)–LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, and BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced the first patient has been treated in a Phase 2a clinical trial of infigratinib in patients…
Read More
Excerpt from the Press Release: SAN FRANCISCO, Aug. 25, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced positive topline results from WHITNEY, the Company’s Phase 2 clinical study of roxadustat, a first-in-class oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of chemotherapy-induced anemia (CIA). WHITNEY is a Phase 2, open label study investigating…
Read More
Excerpt from the Press Release: SAN JOSE, Calif., Aug. 25, 2021 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that a genomic variant analysis indicates that its potential compounds may be even more effective against the Delta variant than the original wild type SARS-CoV-2. While…
Read More
Excerpt from the Press Release: In February, the National Institutes of Health terminated an ambitious clinical trial to study the effectiveness of COVID-19 convalescent plasma in treating patients with mild to moderate disease. The therapy, the NIH determined, showed little benefit in an interim analysis. In a new paper published on Aug. 18 in The New England Journal…
Read More
Excerpt from the Press Release: SÃO PAULO, Brazil and BOSTON, Aug. 24, 2021 /PRNewswire/ — Dasa, the largest integrated healthcare network in Brazil, has chosen to expand upon its partnership with SOPHiA GENETICS SA (Nasdaq: SOPH) to offer the first decentralized HRD (Homologous recombination deficiency) analytics solution in Latin America. HRD is a complex biomarker, important for PARP inhibitors, that helps identify whether…
Read More